IMC Chicago’s Axcelis ACLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$21.8M Buy
115,300
+92,900
+415% +$13.8M 0.01% 1005
2026
Q1
$2.08M Buy
22,400
+2,300
+11% +$204K ﹤0.01% 2528
2025
Q4
$1.61M Sell
20,100
-2,800
-12% -$234K ﹤0.01% 2592
2025
Q3
$2.24M Sell
22,900
-10,900
-32% -$878K ﹤0.01% 2143
2025
Q2
$2.36M Buy
33,800
+7,500
+29% +$428K ﹤0.01% 1890
2025
Q1
$1.31M Sell
26,300
-7,000
-21% -$443K ﹤0.01% 2092
2024
Q4
$2.33M Buy
33,300
+12,500
+60% +$1.04M ﹤0.01% 1750
2024
Q3
$2.18M Sell
20,800
-7,900
-28% -$924K ﹤0.01% 1606
2024
Q2
$4.08M Buy
28,700
+2,800
+11% +$323K ﹤0.01% 1159
2024
Q1
$2.89M Buy
+25,900
New +$3.09M ﹤0.01% 1188

Other funds holding ACLS

IMC Chicago's ACLS Position: Q2 2026 in Review

IMC Chicago sold out of Axcelis (ACLS) in Q2 2026, closing a stake of 6,736 shares — an estimated $999K sold.

IMC Chicago first reported a position in ACLS in Q1 2025 and held it in 2 quarters. The position peaked at $627K in Q1 2026. 441 funds tracked by Wall St. Rank hold ACLS as of Q2 2026.

  • IMC Chicago reported no remaining Axcelis position as of Q2 2026 after selling out during the quarter.
  • IMC Chicago sold 6,736 Axcelis shares in Q2 2026, an estimated $999K.
  • IMC Chicago first reported a position in Axcelis in Q1 2025 and held it in 2 quarters.
  • IMC Chicago's Axcelis position peaked at $627K in Q1 2026.
  • 441 funds tracked by Wall St. Rank held Axcelis as of Q2 2026.

Based on IMC Chicago's 13F filing for Q2 2026, filed 6 Aug 2026.